{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=27",
    "query": {
      "intervention": "Placebo; placebo comparator condition",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 7767,
    "total_pages": 777,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T23:12:30.043Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03512197",
      "title": "A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Midostaurin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 511,
      "start_date": "2018-07-20",
      "completion_date": "2021-02-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512197"
    },
    {
      "nct_id": "NCT06451120",
      "title": "Platelet Rich Plasma Injections In Young And Old Human Subjects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Articular Cartilage",
        "Musculoskeletal Disorders"
      ],
      "interventions": [
        {
          "name": "Platelet-Rich Plasma (PRP) Injections",
          "type": "DRUG"
        },
        {
          "name": "Centrifuge",
          "type": "DEVICE"
        },
        {
          "name": "Control saline injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-01",
      "completion_date": "2027-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451120"
    },
    {
      "nct_id": "NCT00125203",
      "title": "Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type B (Myobloc)",
          "type": "DRUG"
        },
        {
          "name": "Injection of salivary glands",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-07",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125203"
    },
    {
      "nct_id": "NCT03461861",
      "title": "Network-Level Mechanisms for Preclinical Alzheimer's Disease Development",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "APOE 4"
      ],
      "interventions": [
        {
          "name": "AGB101 220 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "55 Years to 75 Years"
      },
      "enrollment_count": 26,
      "start_date": "2019-04-11",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03461861"
    },
    {
      "nct_id": "NCT02116361",
      "title": "OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "onabotulinumtoxinA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 258,
      "start_date": "2014-04-22",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2017-12-19",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 35,
      "location_summary": "Little Rock, Alaska • Bellflower, California • Cerritos, California + 29 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02116361"
    },
    {
      "nct_id": "NCT01826786",
      "title": "The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-42165279 (100 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 43,
      "start_date": "2013-08",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01826786"
    },
    {
      "nct_id": "NCT05975983",
      "title": "Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [
        {
          "name": "INS018_055",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InSilico Medicine Hong Kong Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-02-08",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975983"
    },
    {
      "nct_id": "NCT03298815",
      "title": "Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ocular Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Amniotic Fluid Eye Drops (AFED)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-12-20",
      "completion_date": "2023-02-24",
      "has_results": true,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03298815"
    },
    {
      "nct_id": "NCT06511908",
      "title": "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suicide",
        "Depressive Disorder, Treatment-Resistant",
        "Ketamine",
        "Molecular Mechanisms of Pharmacological Action",
        "Neurotransmitter Agents",
        "Excitatory Amino Acid Agents",
        "Physiological Effects of Drugs",
        "Depressive Disorder, Major",
        "Depressive Disorder",
        "Depression",
        "Mental Disorders",
        "Mood Disorders",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-11-06",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511908"
    },
    {
      "nct_id": "NCT01458574",
      "title": "A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CP690,550",
          "type": "DRUG"
        },
        {
          "name": "CP-690,550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 593,
      "start_date": "2012-07-20",
      "completion_date": "2016-05-27",
      "has_results": true,
      "last_update_posted_date": "2017-05-18",
      "last_synced_at": "2026-10-14T23:12:30.043Z",
      "location_count": 94,
      "location_summary": "Mobile, Alabama • La Jolla, California • Oceanside, California + 47 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01458574"
    }
  ]
}